---
figid: PMC3410405__zlj9991024570001
figlink: /pmc/articles/PMC3410405/figure/F1/
number: F1
caption: Pathophysiology of (A) mammalian target of rapamycin (mTOR) inhibitor–induced
  hyperlipidemia and (B) phosphoinositide 3- kinase–Akt–mTOR pathway inhibitor–induced
  hyperglycemia. LPL, lipoprotein lipase; TG, triglyceride; VDL, very low density
  lipoprotein.
pmcid: PMC3410405
papertitle: Management of Metabolic Effects Associated With Anticancer Agents Targeting
  the PI3K-Akt-mTOR Pathway.
reftext: Naifa L. Busaidy, et al. J Clin Oncol. 2012 Aug 10;30(23):2919-2928.
pmc_ranked_result_index: '60246'
pathway_score: 0.7028804
filename: zlj9991024570001.jpg
figtitle: Pathophysiology of (A) mammalian target of rapamycin (mTOR) inhibitor–induced
  hyperlipidemia and (B) phosphoinositide 3- kinase–Akt–mTOR pathway inhibitor–induced
  hyperglycemia
year: '2012'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3410405__zlj9991024570001.html
  '@type': Dataset
  description: Pathophysiology of (A) mammalian target of rapamycin (mTOR) inhibitor–induced
    hyperlipidemia and (B) phosphoinositide 3- kinase–Akt–mTOR pathway inhibitor–induced
    hyperglycemia. LPL, lipoprotein lipase; TG, triglyceride; VDL, very low density
    lipoprotein.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TG
  - LPL
  - FBN1
  - glucose
genes:
- word: TG
  symbol: TG
  source: hgnc_symbol
  hgnc_symbol: TG
  entrez: '7038'
- word: LPL
  symbol: LPL
  source: hgnc_symbol
  hgnc_symbol: LPL
  entrez: '4023'
- word: mass
  symbol: MASS
  source: hgnc_alias_symbol
  hgnc_symbol: FBN1
  entrez: '2200'
chemicals:
- word: glucose
  source: MESH
  identifier: D005947
diseases: []
figid_alias: PMC3410405__F1
redirect_from: /figures/PMC3410405__F1
figtype: Figure
---
